Resumo

ROCA SERRA, Lisandra et al. Humoral characteristics of head and neck tumors in patients treated with nimotuzumab. MEDISAN [online]. 2018, vol.22, n.5, pp. 470-476. ISSN 1029-3019.

An observational, descriptive and retrospective study of 36 patients included in the (phase IV) clinical trial "Security and effectiveness of nimotuzumab in head and neck tumors" was carried out. It was developed at "Conrado Benítez" Oncological Hospital in Santiago de Cuba, from January, 2013 to December, 2016, aimed at identifying the humoral characteristics of these tumors in the affected patients. The Student t test was used with a statistical significance of p <0.05. There was a prevalence of the male sex in older than 60 years, the clinical adverse effects and the pharynx tumor; the clinical stage III and the well differentiated epidermoid carcinoma were the most frequent findings. There were no statistically significant differences among the laboratory parameters before and during the combined treatment with nimotuzumab. This medication constituted a sure, advantageous and feasible therapeutic alternative as part of the conventional therapeutic plan in assistance conditions

Palavras-chave : monoclonal antibody; nimotuzumab; cancer; secondary health care.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )